Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
about
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.The cell cycle checkpoint inhibitors in the treatment of leukemias.miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer.
P2860
Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Synergism between bosutinib (S ...... stant BCR/ABL⁺ leukemia cells.
@en
type
label
Synergism between bosutinib (S ...... stant BCR/ABL⁺ leukemia cells.
@en
prefLabel
Synergism between bosutinib (S ...... stant BCR/ABL⁺ leukemia cells.
@en
P2093
P2860
P1433
P1476
Synergism between bosutinib (S ...... stant BCR/ABL⁺ leukemia cells.
@en
P2093
Akhil Kolluri
Elisa Hawkins
Haeseong Park
Maciej Kmieciak
Steven Grant
Tri Nguyen
P2860
P356
10.1016/J.LEUKRES.2014.10.009
P577
2014-11-11T00:00:00Z